Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type (Revenue and Volume, 2012-2025)
5.1.1 Insulin Drugs
5.1.1.1 Traditional Human Insulins
5.1.1.1.1 Humilin
5.1.1.1.2 Novolin
5.1.1.1.3 Insuman
5.1.1.2 Basal Insulin or Long-acting Insulin
5.1.1.2.1 Lantus
5.1.1.2.2 Levemir
5.1.1.2.3 Tresiba
5.1.1.2.4 Toujeo
5.1.1.2.5 Basaglar
5.1.1.3 Bolus Insulin or Fast-acting Insulin
5.1.1.3.1 Novolog/NovoRapid
5.1.1.3.2 Humalog
5.1.1.3.3 Apidra
5.1.1.3.4 FIASP
5.1.1.3.5 Admelog
5.1.1.4 Insulin Combinations
5.1.1.4.1 NovoMix
5.1.1.4.2 Ryzodeg
5.1.1.4.3 Xultophy
5.1.1.4.4 Soliqua/Suliqua
5.1.1.5 BioSimilar Insulin
5.1.1.5.1 Insulin Glargine
5.1.1.5.2 Other Biosimilar Insulins
5.1.2 Oral Drugs (Value and Volume, 2012-2025)
5.1.2.1 Biguanides (Metformin)
5.1.2.2 Alpha - Glucosidase Inhibitors
5.1.2.3 Dopamine D2 Receptor Agonist (Bromocriptin)
5.1.2.4 Sodium - glucose cotransport -2 (SGLT-2) inhibitor
5.1.2.4.1 Invokana (Canagliflozin)
5.1.2.4.2 Jardiance (Empagliflozin)
5.1.2.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.2.4.4 Suglat (Ipragliflozin)
5.1.2.5 Dipeptidyl peptidase - 4 (DPP-4) inhibitors
5.1.2.5.1 Sitagliptin (Januvia)
5.1.2.5.2 Saxagliptin (Onglyza)
5.1.2.5.3 Linagliptin (Tradjenta)
5.1.2.5.4 Alogliptin (Vipidia/Nesina)
5.1.2.5.5 Vildagliptin (Galvus)
5.1.2.6 Sulfonylureas
5.1.2.7 Meglitinide
5.1.2.8 Janumet (Sitagliptin and Metformin HCl)
5.1.3 Non-Insulin Injectable drugs (Value and Volume 2012-2025)
5.1.3.1 GLP-1 Receptor Agonists
5.1.3.1.1 Victoza (Liraglutide)
5.1.3.1.2 Byetta (Exenatide)
5.1.3.1.3 Bydureon (Exenatide)
5.1.3.1.4 Trulicity (Dulaglutide)
5.1.3.1.5 Lyxumia (Lixisenatide)
5.1.3.1.6 Janumet (Sitagliptin and Metformin HCl)
5.1.3.2 Amylin Analogue
5.1.3.2.1 Symlin (Pramlintide)
5.2 Geography
5.2.1 Latin America
5.2.1.1 Brazil (Value and Volume 2012-2024)
5.2.1.1.1 By Insulin Drugs (Traditional Human Insulin, Long-acting Insulins, Fast-acting Insulins, Insulin Combinations and Biosimilar Insulins) and By Sub-segment
5.2.1.1.2 By oral Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine D2 Receptor, Sodium-glucose Cotransport-2, Dipeptidyl Peptidase - 4 Inhibitors, Sulfonylureas, Meglitinide, Janumet) By Sub-segment.
5.2.1.1.3 By Non-insulin Injectable drugs (GLP-1 Receptor Agonists, Amylin Analogue) By Sub-segment.
5.2.1.2 Mexico (Value and Volume 2012-2024)
5.2.1.2.1 By Insulin Drugs (Traditional Human Insulin, Long-acting Insulins, Fast-acting Insulins, Insulin Combinations and Biosimilar Insulins) and By Sub-segment
5.2.1.2.2 By oral Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine D2 Receptor, Sodium-glucose Cotransport-2, Dipeptidyl Peptidase - 4 Inhibitors, Sulfonylureas, Meglitinide, Janumet) By Sub-segment.
5.2.1.2.3 By Non-insulin Injectable drugs (GLP-1 Receptor Agonists, Amylin Analogue) By Sub-segment.
5.2.1.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.1.3.1 By Insulin Drugs (Traditional Human Insulin, Long-acting Insulins, Fast-acting Insulins, Insulin Combinations and Biosimilar Insulins) and By Sub-segment
5.2.1.3.2 By oral Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine D2 Receptor, Sodium-glucose Cotransport-2, Dipeptidyl Peptidase - 4 Inhibitors, Sulfonylureas, Meglitinide, Janumet) By Sub-segment.
5.2.1.3.3 By Non-insulin Injectable drugs (GLP-1 Receptor Agonists, Amylin Analogue) By Sub-segment.


6 MARKET INDICATORS
6.1 Type-1 Diabetes population (2012-2025)
6.2 Type-2 Diabetes population (2012-2025)


7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 Takeda
7.1.5 Pfizer
7.1.6 Janssen Pharmaceuticals
7.1.7 Astellas
7.1.8 Boehringer Ingelheim
7.1.9 Merck And Co.
7.1.10 AstraZeneca
7.1.11 Bristol Myers Squibb
7.1.12 Novartis
7.2 Company Share Analysis
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
7.2.5 Astellas
7.2.6 Janssen Pharmaceuticals
7.2.7 Merck And Co.
7.2.8 Other Company Analysis


8 MARKET OPPORTUNITIES AND FUTURE TRENDS